Vijaya Diagnostics on 7 November announced its quarterly report for the July-September quarter.

The company reported a 73.09% year-on-year (YoY) increase in its consolidated net profit at Rs 33.57 crore for the quarter against Rs 23.46 crore reported in the year-ago quarter.

The revenue of the company during the quarter was at Rs 138.85 crore, which is a 15% YoY increase from Rs 120.74 crore reported in the same quarter last year.

The EBITDA (earnings before interest, tax, depreciation, and amortisation) during the quarter was at Rs 57.3 crore, and the EBITDA margins were at 41.3% from 40.4% recorded in the same quarter of the previous fiscal year.

The company was last in the limelight when it appointed SUra Suprita Reddy as a Managing Director and CEO of the company for a period of five years with effect from 1 July 2023. Sura is a part of the promoter and promoter group of the company and has been associated with the firm since 2003 and has been heading the overall strategy, operations, clinical excellence, and expansion of the company since then.

Suprita Reddy, MD & CEO of Vijaya Diagnostics, said, “It gives me great joy to announce that the robust business performance in Q2 showcases a steady 18 percent year-on-year non-COVID revenue growth and an impressive 15 percent quarter-on-quarter rise, demonstrating the positive consolidation of our core business.”